drugset / Trial / NCT05079360
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
RandomizedParallel-groupSingle-blindTreatment
Summary
To demonstrate the efficacy of sabizabulin in the treatment of ER+HER2- metastatic breast cancer (MBC) as measured by progression free survival (PFS) by RECIST v1.1.
Timeline
- Start
- 2023-03-15
- Primary completion
- 2024-03-30
- Completion
- 2024-05-26
Outcome
Outcome not reported
Stopped: “Decided to halt and will potentially reopen in the future.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | — | — |
| Comparator | Exemestane | Small molecule | — | — |
| Subject | Sabizabulin | Small molecule | 32 mg | Oral |